Cargando…

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease

Background: Aβ pathology is associated with longitudinal changes of brain metabolism, atrophy, and cognition, in cognitively healthy elders. However, Aβ information is usually measured cross-sectionally and dichotomized to classify subjects as Aβ-positive or Aβ-negative, making it difficult to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Insel, Philip S., Ossenkoppele, Rik, Gessert, Devon, Jagust, William, Landau, Susan, Hansson, Oskar, Weiner, Michael W., Mattsson, Niklas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434146/ https://www.ncbi.nlm.nih.gov/pubmed/28567001 http://dx.doi.org/10.3389/fnins.2017.00281

Ejemplares similares

Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information
por: Insel, Philip S., et al.
Publicado: (2016)

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly
por: Svenningsson, Anna L., et al.
Publicado: (2019)

Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease
por: Insel, Philip S., et al.
Publicado: (2023)

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
por: Svenningsson, Anna Linnéa, et al.
Publicado: (2022)

The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults
por: Insel, Philip S., et al.
Publicado: (2020)

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
por: Ossenkoppele, Rik, et al.
Publicado: (2019)

Age, vascular disease, and Alzheimer’s disease pathologies in amyloid negative elderly adults
por: Guo, Tengfei, et al.
Publicado: (2021)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
por: Palmqvist, Sebastian, et al.
Publicado: (2017)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
por: Cullen, Nicholas C., et al.
Publicado: (2021)

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Determining clinically meaningful decline in preclinical Alzheimer disease
por: Insel, Philip S., et al.
Publicado: (2019)

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
por: Smith, Ruben, et al.
Publicado: (2020)

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
por: Pereira, Joana B, et al.
Publicado: (2021)

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease
por: Johansson, Maurits, et al.
Publicado: (2021)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
por: Salvadó, Gemma, et al.
Publicado: (2023)

Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
por: Spotorno, Nicola, et al.
Publicado: (2022)

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
por: Tideman, Pontus, et al.
Publicado: (2022)

Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease
por: Mattsson, Niklas, et al.
Publicado: (2013)

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly
por: Hahn, Andreas, et al.
Publicado: (2019)

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
por: Palmqvist, Sebastian, et al.
Publicado: (2016)

Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline
por: Leal, Stephanie L, et al.
Publicado: (2017)

Do genetic factors contribute to sex-specific differences in resilience to amyloid pathology?
por: Groot, Colin, et al.
Publicado: (2022)

Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K, et al.
Publicado: (2017)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2023)

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease()
por: Chételat, Gaël, et al.
Publicado: (2013)

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity
por: Pereira, Joana B, et al.
Publicado: (2019)

Correction: Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t3snm3hjrnsgqoph76k4iakg3g